Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Melanoma
  Free Subscription

Articles published in
J Clin Oncol
    September 2025
  1. MCARTHUR GA
    Next-Generation Oncolytic Viruses to Overcome Resistance to Anti-PD-1 Therapy in Melanoma.
    J Clin Oncol. 2025 Sep 15:JCO2501683. doi: 10.1200/JCO-25-01683.
    >> Share

    July 2025
  2. MARQUEZ-RODAS I, Dutriaux C, Saiag P, de la Cruz Merino L, et al
    Erratum: BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.
    J Clin Oncol. 2025 Jul 24:JCO2501680. doi: 10.1200/JCO-25-01680.
    >> Share

  3. BURTON EM, Milton DR, Tetzlaff MT, Wani K, et al
    Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.
    J Clin Oncol. 2025 Jul 10:JCO2500494. doi: 10.1200/JCO-25-00494.
    >> Share

  4. WONG MK, Milhem MM, Sacco JJ, Michels J, et al
    RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).
    J Clin Oncol. 2025 Jul 8:101200JCO2501346. doi: 10.1200/JCO-25-01346.
    >> Share

    June 2025
  5. MARQUEZ-RODAS I, Dutriaux C, Saiag P, de la Cruz Merino L, et al
    BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.
    J Clin Oncol. 2025 Jun 27:JCO2402595. doi: 10.1200/JCO-24-02595.
    >> Share

  6. DIAB A, Ascierto PA, Maio M, Abdel-Wahab R, et al
    Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).
    J Clin Oncol. 2025 Jun 25:JCO2501412. doi: 10.1200/JCO-25-01412.
    >> Share

  7. MCCLELLAND PH, Nah SK, Gustafson AM, Dinerman AJ, et al
    Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes for Metastatic Acral Lentiginous Melanoma.
    J Clin Oncol. 2025 Jun 13:JCO2402348. doi: 10.1200/JCO-24-02348.
    >> Share

  8. LODDE GC, Hassel JC, von Wasielewski I, Meier F, et al
    Long-term follow-up of real-world adjuvant anti-PD1 checkpoint inhibition and targeted therapy in stage III melanoma patients.
    J Clin Oncol. 2025 Jun 3:101200JCO2402776. doi: 10.1200/JCO-24-02776.
    >> Share

  9. MEDINA T, Chesney JA, Kluger HM, Hamid O, et al
    Long-term Efficacy and Safety of Lifileucel Tumor-infiltrating Lymphocyte (TIL) Cell Therapy in Patients with Advanced Melanoma: A 5-year Analysis of the C-144-01 Study.
    J Clin Oncol. 2025 Jun 2:101200JCO2500765. doi: 10.1200/JCO-25-00765.
    >> Share

    April 2025
  10. SPERDUTO PW, Marqueen KE, Chang E, Li J, et al
    Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment.
    J Clin Oncol. 2025 Apr 17:JCO2401351. doi: 10.1200/JCO-24-01351.
    >> Share

    March 2025
  11. LONG GV, Lipson EJ, Hodi FS, Ascierto PA, et al
    Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.
    J Clin Oncol. 2025 Mar 7:JCO2500452. doi: 10.1200/JCO-25-00452.
    >> Share

  12. DIAB A, Ascierto PA, Maio M, Abdel-Wahab R, et al
    Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).
    J Clin Oncol. 2025 Mar 6:JCO2400727. doi: 10.1200/JCO.24.00727.
    >> Share

  13. WEISS SA, Djureinovic D, Wei W, Tran T, et al
    Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.
    J Clin Oncol. 2025 Mar 6:JCO2402219. doi: 10.1200/JCO-24-02219.
    >> Share

    February 2025
  14. PATEL SP, Sheth RA, Davis C, Medina T, et al
    Combination Immunotherapy With Nivolumab Plus Ipilimumab in Melanoma of Unknown Primary.
    J Clin Oncol. 2025 Feb 6:JCO2401802. doi: 10.1200/JCO-24-01802.
    >> Share

    January 2025
  15. ROTZ SJ, Stratton K, Leisenring WM, Smith SA, et al
    Melanoma Among Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.
    J Clin Oncol. 2025 Jan 8:JCO2401519. doi: 10.1200/JCO-24-01519.
    >> Share

  16. HUANG RY, Youssef G, Nelson T, Wen PY, et al
    Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204.
    J Clin Oncol. 2025 Jan 3:JCO2400953. doi: 10.1200/JCO.24.00953.
    >> Share

    December 2024
  17. TAWBI HA, Hodi FS, Lipson EJ, Schadendorf D, et al
    Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.
    J Clin Oncol. 2024 Dec 13:JCO2401124. doi: 10.1200/JCO.24.01124.
    >> Share

    November 2024
  18. LONG GV, Larkin J, Schadendorf D, Grob JJ, et al
    Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.
    J Clin Oncol. 2024 Nov 6:JCO2400400. doi: 10.1200/JCO.24.00400.
    >> Share

  19. KREFT S, Lorigan P
    Combination Immunotherapy for Advanced Melanoma-How to Choose?
    J Clin Oncol. 2024 Nov 4:JCO2402005. doi: 10.1200/JCO-24-02005.
    >> Share

  20. VERHEIJDEN RJ, de Groot JS, Fabriek BO, Hew MN, et al
    Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials.
    J Clin Oncol. 2024;42:3713-3724.
    >> Share

    October 2024
  21. WEBER JS, Middleton MR, Yates G, Sharpe DJ, et al
    Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials.
    J Clin Oncol. 2024 Oct 8:JCO2400237. doi: 10.1200/JCO.24.00237.
    >> Share

  22. SCHMITT AM, Larkin J, Patel SP
    Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out.
    J Clin Oncol. 2024 Oct 7:JCO2401572. doi: 10.1200/JCO-24-01572.
    >> Share

  23. MARGOLIN KA
    Using Indirect Comparisons of Prospective, Randomized Trials to Make Therapeutic Decisions in Melanoma: Cross-Trial Comparisons as Surrogates for Proper Head-To-Head Studies?
    J Clin Oncol. 2024 Oct 7:JCO2401634. doi: 10.1200/JCO-24-01634.
    >> Share

  24. SARGEN MR, Barnhill RL, Elder DE, Swetter SM, et al
    Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group.
    J Clin Oncol. 2024 Oct 4:JCO2401154. doi: 10.1200/JCO.24.01154.
    >> Share

    September 2024
  25. VALLEJO BA, Ansari A, Parikh SA, Achenbach SJ, et al
    Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell Lymphocytosis.
    J Clin Oncol. 2024 Sep 4:JCO2400332. doi: 10.1200/JCO.24.00332.
    >> Share

    August 2024
  26. LONG GV, Lipson EJ, Hodi FS, Ascierto PA, et al
    First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.
    J Clin Oncol. 2024 Aug 13:JCO2401125. doi: 10.1200/JCO.24.01125.
    >> Share

  27. WEBER J, Del Vecchio M, Mandala M, Gogas H, et al
    Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.
    J Clin Oncol. 2024 Aug 5:JCO2301448. doi: 10.1200/JCO.23.01448.
    >> Share

    July 2024
  28. HARBOUR JW, Correa ZM, Schefler AC, Mruthyunjaya P, et al
    15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1).
    J Clin Oncol. 2024 Jul 25:JCO2400447. doi: 10.1200/JCO.24.00447.
    >> Share

    June 2024
  29. HAMID O, Lewis KD, Weise A, McKean M, et al
    Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.
    J Clin Oncol. 2024 Jun 20:JCO2302172. doi: 10.1200/JCO.23.02172.
    >> Share

    March 2024
  30. SCHENK KM, Deutsch JS, Chandra S, Davar D, et al
    Nivolumab + Tacrolimus + Prednisone +/- Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.
    J Clin Oncol. 2024;42:1011-1020.
    >> Share

  31. LUKE JJ, Ascierto PA, Khattak MA, de la Cruz Merino L, et al
    Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.
    J Clin Oncol. 2024 Mar 7:JCO2302355. doi: 10.1200/JCO.23.02355.
    >> Share

    February 2024

  32. Expression of Concern: Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling.
    J Clin Oncol. 2024 Feb 23:JCO2400161. doi: 10.1200/JCO.24.00161.
    >> Share

  33. VAREY AHR, Li I, El Sharouni MA, Simon J, et al
    Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.
    J Clin Oncol. 2024 Feb 5:JCO2301020. doi: 10.1200/JCO.23.01020.
    >> Share


  34. Erratum: Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling.
    J Clin Oncol. 2024 Feb 1:JCO2400017. doi: 10.1200/JCO.24.00017.
    >> Share

    December 2023
  35. DE VIS JB, Cmelak AJ, Osmundson EC
    Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy?
    J Clin Oncol. 2023 Dec 11:JCO2302151. doi: 10.1200/JCO.23.02151.
    >> Share

    September 2023

  36. Erratum: Systemic Therapy for Melanoma: ASCO Guideline.
    J Clin Oncol. 2023 Sep 18:JCO2301773. doi: 10.1200/JCO.23.01773.
    >> Share

    August 2023
  37. DIAB A, Gogas H, Sandhu S, Long GV, et al
    Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
    J Clin Oncol. 2023 Aug 31:JCO2300172. doi: 10.1200/JCO.23.00172.
    >> Share

  38. HARGRAVE DR, Terashima K, Hara J, Kordes UR, et al
    Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma.
    J Clin Oncol. 2023 Aug 29:JCO2300558. doi: 10.1200/JCO.23.00558.
    >> Share

  39. SETH R, Agarwala SS, Messersmith H, Alluri KC, et al
    Systemic Therapy for Melanoma: ASCO Guideline Update.
    J Clin Oncol. 2023 Aug 14:JCO2301136. doi: 10.1200/JCO.23.01136.
    >> Share


  40. Retraction: Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma.
    J Clin Oncol. 2023 Aug 11:JCO2301358. doi: 10.1200/JCO.23.01358.
    >> Share

    July 2023
  41. ASCIERTO PA, Dummer R, Gogas HJ, Arance A, et al
    Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial.
    J Clin Oncol. 2023 Jul 28:JCO2202322. doi: 10.1200/JCO.22.02322.
    >> Share

  42. ZHANG X, Ferris L, Faries MB, Luke JJ, et al
    Debating Sentinel Lymph Node Biopsy for Melanoma in the Modern Adjuvant Era.
    J Clin Oncol. 2023 Jul 6:JCO2300255. doi: 10.1200/JCO.23.00255.
    >> Share

    June 2023
  43. ROBERT C, Carlino MS, McNeil C, Ribas A, et al
    Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.
    J Clin Oncol. 2023 Jun 22:JCO2201599. doi: 10.1200/JCO.22.01599.
    >> Share

  44. OLSON DJ, Odunsi K
    Adoptive Cell Therapy for Nonhematologic Solid Tumors.
    J Clin Oncol. 2023;41:3397-3407.
    >> Share

  45. DUMMER R, Corrie P, Gutzmer R, Meniawy TM, et al
    First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
    J Clin Oncol. 2023 Jun 12:JCO2202199. doi: 10.1200/JCO.22.02199.
    >> Share

  46. RIELY GJ, Smit EF, Ahn MJ, Felip E, et al
    Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Jun 4:JCO2300774. doi: 10.1200/JCO.23.00774.
    >> Share

    April 2023
  47. LONG GV, Menzies AM, Scolyer RA
    Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.
    J Clin Oncol. 2023 Apr 27:JCO2202575. doi: 10.1200/JCO.22.02575.
    >> Share

    March 2023
  48. DE BRAUD F, Dooms C, Heist RS, Lebbe C, et al
    Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.
    J Clin Oncol. 2023 Mar 22:JCO2202018. doi: 10.1200/JCO.22.02018.
    >> Share

  49. PHADKE MS, Smalley KSM
    Targeting NRAS Mutations in Advanced Melanoma.
    J Clin Oncol. 2023 Mar 22:JCO2300205. doi: 10.1200/JCO.23.00205.
    >> Share

  50. OLOFSSON BAGGE R, Nelson A, Shafazand A, All-Eriksson C, et al
    Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial).
    J Clin Oncol. 2023 Mar 20:JCO2201705. doi: 10.1200/JCO.22.01705.
    >> Share


  51. Erratum: Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed CellDeath Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
    J Clin Oncol. 2023 Mar 20:JCO2300439. doi: 10.1200/JCO.23.00439.
    >> Share


  52. Erratum: COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma.
    J Clin Oncol. 2023 Mar 8:JCO2300385. doi: 10.1200/JCO.23.00385.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016